Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

February 26, 2026

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 43 min

Earnings Call Speaker Segments

Lawrence Keusch

executive
#1

Hello, everyone, and thanks for joining us on the Teleflex Incorporated Year End 2025 Earnings Conference Call this morning. On the line with us today are Stuart Randall, our Interim President and Chief Executive Officer, along with John R. Deren, Executive Vice President and Chief Financial Officer. Stu and John are going to deliver their prepared remarks, and after that, we'll take your questions in a Q&A session. Before we get started, I want to note that certain topics we'll cover on this call will include forward-looking statements about future events, as described in the slides that have been posted to the Investor Relations section of the Teleflex website; we'd like to caution everyone that these statements are, in fact, forward-looking in nature and are subject to risks and uncertainties factors referenced in our press release today, including our Form 10-K, as well as our filings with the SEC, which can be accessed on our website. Actual events or results may differ materially. I'll now hand things over to Stu for his remarks. Stu?

Stuart Randall

executive
#2

To bring everyone up to speed: after we made public the sale of our acute care interventional urology and OEM operations, and with Teleflex starting a new chapter as a company that's leaner and growing faster, the board came to its choice to split from the Chief Executive Officer role. We stay thankful to Liam J. Kelly for the impactful leadership he showed and the meaningful contributions he delivered while he was here. Spencer Stuart, a top executive search firm, is assessing outside candidates, and alongside its help the board is running an active hunt for a CEO. Things are moving at a fast pace, yet we're keeping to a thorough, careful method. That approach lets us find the right individual—someone whose experience and abilities can steer Teleflex toward what lies ahead—while keeping the entire organization operating without disruption. On top of that, throughout this transition, keeping our strategic priorities on track matters greatly. In my role as interim CEO, my focus at this moment is on delivering results. I stepped into this interim seat in January, and I carry with me over 30 years of work across health care and medical devices. For some background, serving on Teleflex's board since 2009 has been a privilege, collaborating closely with our leadership team to keep the company advancing in line with our strategic objectives. Having said that, allow me to take you through the main elements of our strategy. Last December, we signed definitive agreements to sell the acute care, interventional urology, and OEM businesses, with two separate buyers picking them up. Those strategic divestitures should generate total cash proceeds of $2.03 billion, while net after-tax proceeds are expected to land at approximately $1.8 billion. On the most recent updates, we're still working through regulatory and other closing conditions, and we still expect the sales to close in 2026. Put simply, our value creation strategy hasn't shifted at all. We intend to direct these net proceeds toward handing a substantial amount of capital back to shareholders, through the buyback program we previously announced for up to $1.0 billion, while simultaneously reducing debt so we gain added financial flexibility and can support future growth and value creation. Through these steps, we're demonstrating our dedication to disciplined capital allocation and returning money to shareholders. Where it makes sense, we'll continue exploring additional opportunities to return capital to shareholders, consistent with our focus on long-term value creation. We're positioning Teleflex as a medical technologies leader with more flexibility to invest in innovation, and to compete in these priority markets. Going forward, putting money into new products will rank among our top strategic priorities. We expect that R&D costs at RemainCo will reach approximately 8% of sales, while Teleflex historically devoted about 5% of revenue to that area, a figure that equates to $427.5 million. Once we created Teleflex RemainCo, encompassing the businesses we'll keep running, the result was a leaner portfolio that's better tuned, organized around three segments that fit together well: Vascular, where the emergency medicine portfolio now sits; Interventional, which has had the intra-aortic balloon pump portfolio removed; and Surgical. Now some detail on the adjusted EPS guidance we're providing for 2026: the range comes in at $6.25 to $6.55. That said, several assumptions underlie this guidance, and as 2026 plays out and we move toward 2027, those assumptions will have a big bearing on our EPS. First, the range we've handed you incorporates an entire year of stranded costs associated with our strategic divestitures, which we estimate at $90 million. Stranded costs represent the expenses needed to keep both the continuing and the discontinued operations going, and they begin once the strategic divestitures are closed. Second, in order to fully offset those stranded costs I just referred to, we expect the transition services, or TS, and manufacturing services, or MS, agreements to cover them entirely on an annualized basis, recognizing the TS and MS agreements across a transitionary period. Beyond that, we're pursuing expense reduction and have launched an initial restructuring plan designed to mitigate about $50 million of cost, so the organization ends up appropriately sized following the divestitures. Last, our 2026 adjusted EPS outlook leaves out the favorable effect we foresee from our announced intentions to buy back $1.0 billion of common stock and pay down debt using the remaining strategic divestiture proceeds, with both actions planned for completion after those transactions close. We expect these moves to bring about a meaningfully lower share count and a sizable reduction in interest expense. Even though we haven't factored the benefits of these moves into our 2026 adjusted EPS guidance, we still anticipate the strategic divestitures wrapping up during 2026. All things considered, we project these dynamics will drive a significant increase in adjusted EPS by 2027 and beyond. Having said that, let me turn to what we'll be covering for the rest of today's call. To begin, we'll walk through the results from our continuing operations, and then we'll wrap up with our 2026 financial guidance. Before we get started, I want to note that the assets tied to the strategic divestitures still pending — acute care, interventional urology, and OEM — have been reclassified as discontinued operations. That move aligns with our intention to separate the company, gives a clear view of RemainCo's ongoing performance, and satisfies accounting guidance requirements. My comments will address continuing operations only for 2025, and those numbers reflect the Biotronik vascular intervention business we purchased. Unless I say otherwise, any growth rate I cite is adjusted, constant currency, and compared with the prior year. Additionally, we recorded $427.5 million in connection with these matters. Regarding pro forma adjusted constant currency growth, there are two items we leave out: the $9 million Italian payback item in 2025, and about $14 million associated with RemainCo product revenue, spanning global product categories we stopped offering in 2025 after a strategic realignment. Revenue generated by the acquired vascular intervention business during the comparable earlier period is included in the guidance for pro forma adjusted constant currency growth. Moving on, let's cover second half 2025 continuing operations revenue, broken out by global product category. One note before proceeding on how 2025 figures will be addressed: growth references for our global product categories from continuing operations will be shown on a pro forma adjusted constant currency basis against the prior year, unless otherwise stated. Starting with Vascular: revenue came to $472.7 million, a 2.4% gain over the equivalent quarter last year, including an 8.1% increase fueled mostly by advances in our central access, hemostatic, and atomization products, partially offset since military surge orders from before were absent in 2025. Turning to Interventional: a broad-based interventional lineup produced a strong second-half showing, with reported vascular intervention revenues for 2025 reaching $202 million. In our Surgical segment, revenue was $219.3 million, rising 3.2%, reflecting volume-based procurement in China set against a tough comparison with the prior year period. Underlying trends in the core surgical franchise remained solid, as most of our franchises posted strong double-digit growth. That covers my remarks on second half revenue performance. I'd now like to pass the call to John so he can take everyone through our financial results in more detail. John?

John R. Deren

executive
#3

Thanks, Stu, and good morning to everyone. All the numbers I'll reference pertain to continuing operations for 2025. Given the reclassification into discontinued operations, the prior-period continuing operations reflect the impact of stranded costs in each period presented. Since Stu has already gone over revenue, I'll begin with margins. For 2025, adjusted gross margin landed at 63.7%. That represents a drop of 200 basis points versus the prior year, primarily caused by tariffs pressuring results, the vascular intervention acquisition carrying a gross margin a bit under the company average, elevated operating expenses associated with that acquisition, and adverse foreign exchange rates. Adjusted net interest expense totaled $93.6 million in 2025, compared with $77.4 million a year earlier. That rise mostly reflects borrowings used to finance the vascular intervention acquisition, and to a lesser extent, increased logistics and distribution costs along with foreign exchange. For the full year, adjusted operating margin was 22.7%. Our adjusted tax rate in 2025 was 12.6%, compared with 13.4% the previous year. This decrease is primarily due to favorable tax provisions under the recently enacted One Big Beautiful Bill Act, including the ability to deduct U.S.-based R&D expenses. Turning to the bottom line, adjusted earnings per share for 2025 came to $6.98, an 8.7% increase over the prior year. That improvement is largely driven by higher revenue and adjusted operating income, aided by the vascular intervention acquisition, together with a lower tax rate and reduced share count, partially offset by headwinds from interest expense and foreign exchange. At the end of the fourth quarter, cash, cash equivalents and restricted cash equivalents were $402.7 million, versus $285.3 million at the close of 2024. As we've mentioned, 2026 results will include several temporary factors related to our strategic divestitures that will pressure near-term performance; we anticipate these will be offset once both transactions are completed, eventually yielding a clearer financial picture with substantial improvements in margins, interest expense, and adjusted earnings per share. Okay, with that context, I'd like to walk through what's driving our 2026 results. First, we expect to absorb roughly $90 million of stranded costs in 2026 due to the classification of the discontinued operations. We continue to expect the strategic divestitures to close at some point in 2026, and after they do, the transition service agreements and manufacturing service agreements should fully cover those stranded costs on an annualized basis. One key point: prior to those divestitures closing, any cash generated by the discontinued operations will flow to RemainCo, which lessens the economic impact of stranded costs on the company until the transition service and manufacturing service agreements are completely offsetting them. So our initial 2026 guidance incorporates RemainCo's fully burdened cost structure, including approximately $90 million in stranded costs. Second, the exact timing of when the strategic divestitures close will dictate how quickly we can deploy capital during 2026. Once those proceeds are received, we'll deploy them through our capital deployment plans. I want to start by reminding everybody that we expect the after-tax net proceeds from the divestitures to land at approximately $1.8 billion. We remain committed to returning a significant portion of capital to our shareholders through the $1.0 billion share repurchase authorization that we announced previously, as well as through our intention to reduce debt with the remaining proceeds from the strategic divestitures. As we look at 2027 and past that, it's our view that these capital deployment moves — combined with what we receive from the transition service arrangements and manufacturing service arrangements, plus our continued work to reduce stranded costs and right-size the organization — will drive a meaningful lift in adjusted EPS. Let me now shift to our 2026 guidance and take you through it. One key point to keep in mind: this guidance covers continuing operations only, which means the acute care, interventional urology, and OEM businesses are excluded. In comparing 2026 to the prior year, our guidance assumes pro forma adjusted constant currency growth. Several items are excluded from that figure: the $9 million Italian payback measure from 2025, a $14 million foreign exchange effect, and approximately $14 million in product revenue that was discontinued during 2025 as part of a strategic realignment. Vascular intervention revenue is included in the pro forma adjusted constant currency growth guidance for 2026. For 2026, we expect pro forma adjusted constant currency revenue growth of 4.5% to 5.5%. To give you a frame of reference for that 2026 outlook, continuing operations delivered 4.7% pro forma adjusted constant currency revenue growth in 2025. That gives us a strong base as we look toward a revenue growth profile in the mid-single digits, and looking ahead we remain confident in our ability to hit that target. Moving on to adjusted earnings per share. For 2026, we're expecting a range of $6.25 to $6.55. As before, this reflects a set of assumptions and excludes several factors that have already been discussed. Beyond that, as you build your models, please keep these points in mind: we expect adjusted operating margin for 2026 to come in at approximately 19%, which includes the full impact of about $90 million in stranded costs related to the separation activities, with no offsetting benefit from transition service and manufacturing service agreements during 2026. Also worth noting: baked into that 2026 operating margin figure is roughly 8% of sales going toward R&D. And importantly, if you account for the favorable effects from transition service arrangements as well as manufacturing service arrangements, we calculate our underlying steady-state adjusted operating margin at about 23% — that's 400 bps above the fully burdened adjusted operating margin guidance we've provided for 2026. Once the strategic divestitures are complete, we expect at least $90 million on an annualized basis from recognition of transition service and manufacturing service agreements, which is enough to fully offset stranded costs, and that amount will be netted within our expenses. This also represents a 230 basis point improvement in our underlying margin profile relative to the fully burdened guidance. To start tackling that stranded cost total of approximately $90 million, our board has approved — and we shared this in the press release issued today — a restructuring plan designed to eliminate a portion of that weight, make operations across the globe more efficient, and reinforce our cost foundation over the long term, primarily through reducing headcount and rationalizing capital assets, which brings expenses down and improves how efficiently we operate. We expect these actions to be mostly finished by the middle of 2028. Roughly $50 million in annual pretax savings should come from this restructuring. Looking ahead, over the years to come we see opportunities to raise adjusted operating margin by leveraging revenue growth as well as further cost-cutting measures that go beyond our steady-state margin profile of approximately 23%, along with a 230 basis point contribution from these initiatives. Now on to below-the-line assumptions. For the full year 2026, net interest expense is expected to land close to $105 million. Included in that number is the refinancing of our $500 million 4 5/8 senior notes, which come due in November 2027. Finally, we're assuming a tax rate of roughly 13.5% for 2026. Regarding shares outstanding, our 2026 guidance assumes no buybacks, which means a share count approximately consistent with 2025. That said, as each strategic divestiture is completed, we stay committed to executing our $1.0 billion share repurchase program and will continue to refresh our guidance throughout the year. That concludes my prepared remarks. I'll turn it back over to Stu now for some closing comments.

Stuart Randall

executive
#4

Thank you, John. To wrap up, I want to walk through three main points from Q4. To start, Teleflex is undergoing a transformation that refines what we offer, builds a more concentrated medical technologies frontrunner, and sets us up for significant chances to create value down the road. Watching how dedicated and driven our people have been in serving customers, patients, and shareholders is truly motivating. Next, RemainCo posted robust pro forma adjusted constant currency growth, coming in at 4.7% versus the prior year during 2025. That 2025 growth figure—covering the stretch when the vascular intervention business has been ours—along with our 2026 pro forma constant currency growth outlook of 4.5% to 5.5%, aligns with the mid-single-digit growth pattern we target and strongly signals the steady expansion potential of the business we're keeping. We still anticipate both strategic divestitures wrapping up during 2026. And we stay dedicated to deploying the projected $1.8 billion in after-tax proceeds from these deals to give substantial capital back to shareholders via a $1.0 billion share repurchase program, while simultaneously paying down debt to strengthen our financial flexibility and back future expansion and value creation. Finally, once these transactions close, we'll be able to record TS and MS fees, which should total no less than $90 million and completely cover stranded costs on an annualized basis. We're also hard at work cutting expenses through the restructuring announced today, which aims for roughly $50 million in savings. With a leaner portfolio and well-defined strategic goals, we'll be positioned strongly to deliver lasting results and long-term value for shareholders. We anticipate our financial results strengthening across 2026 and then fully capturing the payoff of our work in 2027 and afterward, with substantial gains in adjusted earnings per share. That wraps up what I prepared to say. I'll now hand the call back to the operator for the Q&A portion.

Mike Matson

analyst
#5

Yeah, thanks. So regarding what we do with the money from the divestitures — you've got that $1,000,000,000 buyback authorization, and I believe I heard you say the plan is to use all of it. Could you maybe talk about how that $1,800,000,000 breaks down between repurchasing shares and paying down debt? And then on the restructuring savings, the $48,000,000 to $52,000,000, I think that's what the press release mentioned — was any portion of that already included in the $6.25 to $6.55 EPS guidance range?

John R. Deren

executive
#6

Well, yeah. Since you've already gotten me going. So the share repurchase gets $1,000,000,000. And as for that remaining $800,000,000, we're committed to reducing debt. The deferred draw revolver that we arranged for the Biotronik acquisition comes to roughly $700,000,000, and the other $100,000,000 will go toward our revolver; as for your question on restructuring, the current restructuring includes certain 2026 savings that are already reflected in the guidance. And there's some nuance there. We also announced a further restructuring in Q4 related to the Biotronik acquisition, and that one will contribute additional savings after 2026. So between the two restructurings, we also have line of sight on $50,000,000 post 2026.

Lawrence Keusch

executive
#7

Alright, thank you for those questions, Mike. Now we'll take our following question from Jayson Tyler Bedford at Raymond James. Jayson, the floor is yours.

Jayson Bedford

analyst
#8

Morning, and thanks for laying all that out. I can see there's a lot going on, so I'd like to ask about that 4.7% pro forma increase in the back half. Can you give me either a number for the first half or one for the entire year — I'm just trying to compare like with like? Then, regarding Surgical, you said most franchises saw double-digit growth. What's behind that double-digit growth, and how much of the VBP effect remains for 2026?

John R. Deren

executive
#9

Jayson, our view is that the 4.7% best reflects the growth profile in the areas where we own Biotronik. I'd say this gives you a chance to build your model using that 4.7% together with the guidance we've provided.

Lawrence Keusch

executive
#10

When we look at the entire year, organic growth isn't something we're going to address. All of it has been folded into the pro forma figure, reflecting momentum pretty much everywhere in the portfolio. A particular bright spot is our instrument portfolio, which has now been showing strength for a number of quarters; the instrument line has been refreshed. And bear in mind that this instrument portfolio is primarily focused on procedures involving the ear, nose, and throat. Naturally, ligation remains a solid growth contributor, apart from China, where VBP has been taking a toll; so those are more or less the main drivers inside Surgical.

Stuart Randall

executive
#11

Right. And I'd add that, too, once we move into 2026, we've got automatic appliers positioned to deliver some solid growth, and EMEA holds some genuine opportunity for that expansion. Great.

Brad Bowers

analyst
#12

Alright, starting with cost. We're receiving the complete sales profile. I just wanted to find out where things stand regarding the pro forma cost profile — are there any stranded costs worth mentioning?

John R. Deren

executive
#13

Well, beginning with costs, you're receiving the complete sales profile. Regarding that pro forma cost profile, certain items can't be tied directly to the disposition, yet you still have to operate the entire company. So some overhead burden is present, and sadly, accounting rules prevent you from allocating it; they force you to retain it within continuing operations. And as we've mentioned, $90,000,000 in stranded costs is sitting in our P&L. We continue to manage that business, and although it remains in discontinued ops, we still can utilize those cash flows; and as we've disclosed and discussed, we're seeking ways to fully mitigate that — initially via the TSA and MSA arrangements, and ultimately, through restructuring programs. Our intention is to pursue that full $90,000,000.

Lawrence Keusch

executive
#14

I'd also mention that when you review the adjusted income statement for 2025 that's included in our materials, it likewise incorporates the stranded costs tied to continuing operations. So those are already reflected in it too.

Shagun Singh

analyst
#15

Thanks a lot. So, clearly, 2026 is a year of transition, but could you give us some insight into how the company may look in 2027 and after? Perhaps discuss strategic priorities, how we ought to think about sales growth, margin profile, and where the company could head past that; and then my second question concerns the CEO search. Who is the right leader for this position, and what qualities or experience are you seeking? Thank you.

John R. Deren

executive
#16

I will begin with your first question and consider the mid-single-digit growth. If you start and think about 2027 with our capacity to remove the stranded costs, our capacity to pay down a significant amount of debt, and then repurchase shares, with your own math, I think you will discover a really nice underlying op margin; and then with the share buyback, you should find yourself arriving at a significant uplift in the EPS. I do not have guidance for 2027, but I will let you do that math.

Stuart Randall

executive
#17

Regarding the CEO search, as we've shared before, we're partnering with Spencer Stuart on that effort. Our attention is squarely on individuals who've shown they can run a mid-size, high-growth organization across the globe, with a strong emphasis on high-acuity hospital settings.

Ravi Misra

analyst
#18

Hi there, and thank you for letting me join the call. There are a handful of things I'd like to ask about. Given the tariff rulings handed down not long ago, can you walk us through what could drive us back up to roughly the mid-20s or beyond? Thanks. And also help us gauge how quickly that might unfold, because with the cost-reduction program you've launched and the mitigation coming in next year — at the moment we're at approximately the low-20s. Is that the right level to use going forward as our baseline?

John R. Deren

executive
#19

Correct. What I'd highlight is operating leverage — start with eliminating the stranded costs, and once you've done that, layer back in the mitigation associated with them; how you model that is up to you. Regarding tariffs, our plan does incorporate the duties that were expected as of last week, before the Supreme Court's decision came out. Today, frankly, there's substantial uncertainty about whether those additional tariffs end up at 10%, at 15%, or at some other number. We built in about $18,000,000 of incremental tariffs for this year, and beyond that, a great deal of what's already baked into our plan lives on our balance sheet. Because of all that uncertainty, our plan remains exactly as it was before the Supreme Court ruled. So some upside likely exists. Having said that, I'm not in a position to guarantee it. Of course, the savings drop off quite a bit when you're looking at the 10% to 15% range, and after that you have to wonder whether 150 days marks the end. Might the administration seek another avenue to levy tariffs? At this stage, no one truly knows, and plenty of people think recovering a refund from the federal government will prove very hard indeed — a matter of something like $35 million. Tariffs we pay get capitalized into inventory. So that process would occur and in time flow through into the P&L. Typically you're looking at a wait of at least two quarters before any relief materializes. We'll share updates with everyone as we find out more over the next several days.

Matthew O'Brien

analyst
#20

To put it plainly, John, you're reluctant to discuss 2027 in depth. Still, when I run the numbers on the stranded cost, the possible gains from paying down debt, plus the buyback for this year — and I realize it's entirely pro forma and you won't complete all of it this year — I'm arriving at something closer to $9.5, nearly $10 in earnings for this year. Is that a reasonable way to frame what the pro forma 2026 figure might be? I also have one more question. Thanks.

John R. Deren

executive
#21

Yeah. I won't validate your model. My sense is there's some upside in there as well, and the truth is we'll simultaneously have certain restructuring benefits occurring; so restructuring is one piece, and covering the TSA, MSA costs is another. If your model covers 2027, I'd expect you ought to be able to generate some leverage assuming you're contemplating mid-single-digit growth. So that opportunity exists, and I can't account for how you're arriving at your share count; that will certainly be a matter of debate tied to share price, but my guess is you'd land nearer to that $10 or higher range, that's my view. And I'd add that you should be incorporating sizable interest savings into your 2027 model.

Lawrence Keusch

executive
#22

And once more, let me make it clear that our plan is absolutely to put the money from these transactions to work — $1.0 billion going toward buying back shares, with the other $800 million used to pay down debt.

Larry Biegelsen

analyst
#23

Hey, everyone. Are you able to hear me?

Mike Polark

analyst
#24

Hello there. Good morning. I didn't pick up much regarding the Biotronik integration. Could we just receive an update on how things are progressing? Salesforce? Retention, cross-selling between the U.S. and Europe, what have the highlights been up to now? Any difficulties that have come up? As a follow-up, I'd like to inquire about R&D as a broad idea — 8% as a share of revenue for RemainCo. Could you remind us, is that increase compared to historical Teleflex fully accounted for by Biotronik and a few of the pipeline items there? Or does RemainCo plan to boost investment in Surgical, existing Interventional, and Vascular? For probably, what, 2 years. But after those disappear, do you have enough momentum, I suppose, to keep growing margins once the TSAs end in a few years?

John R. Deren

executive
#25

You know, I believe it's going well. The Salesforce integration is underway. The bags have been merged for the Salesforce, and we believe there's considerable potential for revenue synergies ahead. We've managed to retain, so no major regrettable losses from where we stand. If you look back to Q4, we announced a restructuring tied to the VI acquisition; that has started off nicely. We anticipate very much the back half of the year and a bit into the first half of Q1. It's going well; on R&D, yes, Biotronik arrived with a greater level of R&D. As total Teleflex, we were around 5%. Now, with the discontinued business, we're around 5%. Beyond what Biotronik was investing, we've made some choices to add extra R&D resources for the Interventional area, and then next would be in the Vascular area, we've boosted our R&D too. Surgical, I'd say, to a smaller degree. There are far larger investment possibilities in the Interventional and Vascular areas. When the TSAs end, there's going to be a bit of overlap here with some of the restructurings and while we're receiving TSA revenue. In fact, it might create a bit of a headwind as we move into later years because we'll have a bit of both occurring simultaneously; but our aim is to fully mitigate and offset those stranded costs. Bear in mind, the op margin profile with the growth profile should also add to some substantial leverage over time to keep pushing up that op margin by itself. We'll keep examining cost-saving initiatives. As an organization, we've been very lean on the OpEx side, and we'll keep seeking those opportunities. That's sort of our long-term thinking, so to speak. Again, we don't have a long-range plan set yet, but I think that's the actual opportunity.

Stuart Randall

executive
#26

Also, I'd say those teams are now completely combined and collaborating. They're establishing solid marketing strategies. So I'm quite optimistic about how the sales teams have come together and the prospects ahead of them. This is Stu. I'd simply add that over the past 2 weeks, I attended our sales training gatherings for Asia and North America.

Travis Steed

analyst
#27

Hi, everyone. I suppose if we look forward a bit, clearly the TSAs will counterbalance a great deal of the one-time items. It sounds like you likely can keep increasing earnings and drive EPS leverage down the road. Could you discuss 2027 and past that?

John R. Deren

executive
#28

Certainly. After you more or less absorb those expenses, the genuine possibilities come from that P&L leverage as growth continues — you hold a large portion of that OpEx steady, and the result is a significantly improved op margin. That is roughly how we think over the long term. And I believe a portion of that leverage potential is present in 2026 too, along with 2027. It is not merely about resetting the base during 2027.

Larry Biegelsen

analyst
#29

All right. Thank you. My apologies for that; the call dropped a few times. I hope this hasn't come up already. Regarding 2026 revenue — you had 4.7% growth in 2025. Guidance implies comparable growth for 2026. So what gives you the confidence to begin the year at that level, especially since you've had a few stumbles lately, and there's no permanent CEO in place? Thanks for fielding the questions, folks; that's my first one. And maybe just quickly, John, a second thing: any phasing thoughts for 2026 on revenue and margins?

John R. Deren

executive
#30

Sure; Larry can walk you through some of the cadence in more detail afterward, but expect a step up across the four quarters from the start of the year, driven by the recent integration and the new combining of the bag. There's also a step up as the year progresses for that sales synergy to kick in. And again, because of the comps, the VBP impacts in 2025 hit harder in the second half, so the comps become a bit easier in the second half. We'll still see some VBP impacts in 2026, probably in our Surgical business. But we believe the bulk of VBP is now behind us.

Lawrence Keusch

executive
#31

Thank you, and thank you to everyone that joined us on the call today.

Lawrence Keusch

executive
#32

This concludes the Teleflex Incorporated Year End 2025 Earnings Conference Call.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.